Pharmacy Legislation: Canadian Federal and Provincial Frameworks

Comprehensive vocabulary flashcards covering Canadian federal and provincial pharmacy legislation, regulatory bodies, drug approval stages, scheduling frameworks, labeling standards, and drug distribution rules based on PHAR1210 lecture modules.

Legislation

The formal body of laws created and enacted by an official government body (such as Parliament federally or a Provincial Legislature) to organize society, protect public safety, and govern professional practice.

Bill

A proposed piece of legislation introduced to Parliament or a Provincial Legislature for debate, committee review, and approval before being enacted into law.

Act

Statutory law that has been formally passed and enacted by Parliament or a Provincial Legislature (e.g., the Food and Drugs Act, the Canada Health Act, and the Pharmacy Act, 1991).

Regulation

Detailed, legally binding rules that outline how the general principles of an enabling Act are to be applied, administered, and enforced in daily practice.

By-laws

Administrative and operational rules established by a self-regulatory professional body (such as the Ontario College of Pharmacists) to govern internal operations and the conduct of its registered members.

Schedules (Legislation)

Formal lists appended to an Act or Regulation that organize drugs, chemical substances, medical conditions, or regulated activities into distinct legal categories.

Standards of Practice

Mandatory benchmarks and professional expectations set by a regulatory college that pharmacists and pharmacy technicians must meet to ensure competent, ethical, and safe patient care.

Guidelines

Advisory recommendations and suggested best practices published by regulatory bodies to help practitioners interpret and comply with legislation and standards.

Health Products and Food Branch (HPFB)

The overarching branch of Health Canada responsible for managing the federal regulatory review and oversight of drugs, medical devices, biologics, and natural health products.

Pharmaceutical Drugs Directorate (PDD)

The directorate within HPFB (formerly known as the Therapeutic Products Directorate, or TPD) that evaluates the safety, efficacy, and quality of prescription pharmaceutical drugs for human use.

Biologic and Radiopharmaceutical Drugs Directorate (BRDD)

The federal HPFB directorate (formerly BGTD) responsible for regulating biological drugs derived from living organisms (such as vaccines, blood products, and gene therapies) and radiopharmaceuticals for human use.

Natural and Non-prescription Health Products Directorate (NNHPD)

The regulatory directorate of Health Canada established in $2004$ that oversees the sale, safety, efficacy, and quality of natural health products, homeopathic medicines, vitamins, and non-prescription drugs.

Medical Devices Directorate (MDD)

The directorate under HPFB responsible for assessing the safety, effectiveness, and quality of medical devices (ranging from pacemakers to glucose meters) under the Food and Drugs Act and Regulations.

Marketed Health Products Directorate (MHPD)

The HPFB directorate that coordinates post-market safety surveillance, collects and evaluates adverse drug reaction (ADR) reports, monitors risk signals, and oversees product recalls across all marketed therapeutic categories.

Canada Vigilance Program

Health Canada's post-market surveillance program operated through MedEffect Canada for the collection, evaluation, and dissemination of reported suspected adverse reactions to marketed therapeutic products.

Patent Protection (Canadian Pharmaceuticals)

A legal exclusivity grant issued for $20\text{ years}$ from the date of filing, allowing the innovator pharmaceutical company to manufacture and market a new drug without generic competition.

Pre-clinical Testing

A $3\text{ to }5\text{ year}$ laboratory phase preceding human testing where an isolated, purified substance is tested on tissue cultures and small animals to evaluate pharmacodynamics, toxicology, and dosage stability.

Clinical Trial Application (CTA)

A formal submission made to Health Canada (averaging approximately $1,400$ annually) requesting regulatory authorization to administer an investigational drug to human clinical trial subjects.

Phase I Clinical Trial

A clinical testing stage lasting $6\text{ to }9\text{ months}$ using $20\text{ to }100$ healthy human volunteers to determine drug tolerance, absorption, metabolism, and excretion; approximately $70\%$ of investigational drugs pass this stage.

Phase II Clinical Trial

A clinical testing stage taking $6\text{ months to }3\text{ years}$ involving $100\text{ to }300$ patients with the targeted medical condition to assess optimal dosage ranges and detect short-term adverse effects.

Phase III Clinical Trial

A multi-year ($1\text{ to }5\text{ years}$), double-blind clinical study involving $1,000\text{ to }3,000$ disease-afflicted patients to confirm clinical effectiveness, determine dosing regimens, and detect broader side effects; only about $10\%$ of initial investigational drugs reach this stage.

Notice of Compliance (NOC)

Official marketing authorization issued by Health Canada following the review of a New Drug Submission (NDS) confirming that a product meets safety, efficacy, and quality standards for Canadian sale.

Drug Identification Number (DIN)

A unique eight-digit computer-generated number assigned by Health Canada to each authorized drug product marketed under the Food and Drugs Act and Regulations.

Vanessa's Law

The Protecting Canadians from Unsafe Drugs Act, which amended the Food and Drugs Act to mandate adverse reaction reporting by hospitals, permit mandatory drug recalls, and order post-market label revisions.

Special Access Program (SAP)

A Health Canada program that allows authorized medical practitioners to request custom access to non-marketed or unapproved medications for patients with serious or life-threatening conditions when conventional treatments have failed.

Canada Health Act (CHA)

Federal legislation enacted in $1984$ that outlines the principles and standards provincial and territorial health insurance programs must satisfy to receive full cash funding through the Canada Health Transfer.

Five Criteria of the Canada Health Act

The core statutory pillars of the Canada Health Act: Public Administration, Comprehensiveness, Universality, Portability, and Accessibility.

Pharmacy Regulatory Authority (PRA)

A provincial or territorial licensing body (e.g., the Ontario College of Pharmacists) with the statutory mandate to regulate individual practitioners, license pharmacy premises, enact by-laws, and uphold public protection.

Good Manufacturing Practices (GMP)

The part of quality assurance that ensures therapeutic goods are consistently produced and controlled to quality standards appropriate to their intended use as defined in marketing authorizations.

Probiotic

Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.

Homeopathy

A therapeutic system founded on the principle that disease can be managed using minute, highly diluted quantities of substances that produce similar symptoms in healthy individuals.

Natural Product Number (NPN)

An eight-digit numerical identifier printed on the labels of natural health products indicating that Health Canada has assessed and authorized them for safety, efficacy, and quality.

Homeopathic Medicine Number (DIN-HM)

An eight-digit authorization number issued by Health Canada specifically to identify licensed homeopathic medicines sold in Canada.

Schedule 1 (Natural Health Products Regulations)

An inclusionary schedule outlining permissible natural substances (such as medicinal plants, plant extracts, probiotics, amino acids, essential fatty acids, and specific vitamins) eligible for classification as Natural Health Products.

Schedule 2 (Natural Health Products Regulations)

An exclusionary schedule detailing substances ineligible for regulation as Natural Health Products, including radiopharmaceuticals, Schedule D biologics, tobacco, injectable dermis-puncturing substances, and cannabis containing more than $10\,\mu\text{g/g}$ of THC.

Drug (FDA Definition)

Any substance or mixture manufactured, sold, or represented for the diagnosis, treatment, mitigation, or prevention of disease; for restoring, correcting, or modifying organic functions; or for disinfection in food-handling premises.

Cosmetic (FDA Definition)

Any substance or mixture manufactured, sold, or represented for use in cleansing, improving, or altering the complexion, skin, hair, or teeth (including deodorants and perfumes), which is legally prohibited from carrying drug treatment claims.

Schedule A (Food and Drugs Act)

A statutory list of diseases, disorders, or abnormal physical states (e.g., acute anxiety, asthma, cancer, diabetes) for which therapeutic cures, treatments, or preventatives cannot be advertised to the general public.

Reminder Ad

A direct-to-consumer advertisement format permitted under Schedule A restrictions that displays the drug brand name but mentions neither its therapeutic indication nor health claims.

Help-Seeking Ad

A direct-to-consumer advertisement format permitted under Schedule A restrictions that discusses symptoms of a disease or condition and advises consulting a healthcare professional without referencing any specific brand or medication.

Schedule B (Food and Drugs Act)

A list of authoritative pharmacopeias and formularies (such as the USP, BP, CF, and NF) designated as recognized standards for drug purity, quality, and testing.

Schedule C (Food and Drugs Act)

The schedule under the Food and Drugs Act specifying radiopharmaceuticals (drugs containing radioactive materials) and their non-radionuclide chemical preparation precursors.

Schedule D (Food and Drugs Act)

The schedule under the Food and Drugs Act regulating biologic products derived from living systems or biotechnological methods, including blood products, insulins, vaccines, and allergenic extracts.

Double-Doctoring (Section 31 FDA)

The illegal act of seeking or receiving a prescription or drug from a practitioner without disclosing details of all prescriptions obtained from other prescribers within the preceding $30\text{ days}$.

Lot Number

Any distinctive combination of letters, figures, or both by which a food or drug product can be tracked through manufacturing processes and identified in commercial distribution.

Official Drug

A drug for which standards of identity, purity, and potency are established in the Food and Drug Regulations or recognized in a Schedule B compendium publication.

Parenteral Use

The administration of a medicinal substance through or into the skin or mucous membranes using a hypodermic syringe, needle, or specialized medical instrument.

Canadian Standard Drug (CSD)

Specific drugs listed in Division 6 of FDR Part C (such as conjugated estrogens, digoxin, gelatin, and thyroid) that are subject to dedicated Canadian manufacturing and purity specifications.

Controlled Drug Symbol

A diamond-shaped outline enclosing the letter 'C' required to appear on the upper left-hand corner of the principal display panel for drugs governed by Part G of the Food and Drug Regulations.

Narcotic Drug Symbol

A solid square enclosing the letter 'N' in a contrasting colour, displayed on the upper left-hand corner of the principal display panel for Schedule I CDSA narcotics.

Targeted Substance Symbol

A square symbol containing a diagonal dividing line with the letter 'C' in the upper section and 'T' in the lower section, used for benzodiazepines and other targeted substances.

Opioid Warning Sticker

A mandatory yellow auxiliary label containing an inverted white caution triangle with an exclamation point and the text 'Opioids can cause DEPENDENCE, ADDICTION and OVERDOSE', affixed to Class A opioid containers.

Prescription Drug List (PDL)

An official Health Canada registry under FDR Part C specifying non-controlled medicinal ingredients that require a prescription for sale in Canada, divided into Part I (human use) and Part II (veterinary use).

Prescription Transfer

The formal professional procedure whereby all remaining refills for a prescription are transferred directly between two pharmacies by a pharmacist or regulated pharmacy technician, rendering the original record void.

Canadian Drug Facts Table (CDFT)

A standardized, high-legibility table mandated under Plain Language Labelling regulations for the outer packaging of all non-prescription medications in Canada.

Part G (Food and Drug Regulations)

The regulatory division controlling the production, distribution, sale, and record-keeping of controlled substances (Part I: amphetamines, Part II: barbiturates, Part III: anabolic steroids).

Part J (Food and Drug Regulations)

The regulatory division restricting the possession and handling of restricted substances (such as LSD, psilocybin, MDA, and Salvia divinorum) exclusively to licensed dealers, clinical researchers, and law enforcement.